ReviewCurrent cardiology reports2025
Cardiovascular Risk Factor and Atherosclerosis in Rheumatoid Arthritis (RA).
Review in Current cardiology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Diagnostic, prognostic and therapeutic biomarkers in rheumatoid arthritis.Nature reviews. Rheumatology · 2026Review
- Carotid Atherosclerosis and T-Cell Imbalance in Women with Rheumatoid Arthritis: A Cross-Sectional Study of Intima-Media Thickness, Anti-CCP Antibodies and CD4/CD8 Ratio.Journal of clinical medicine · 2026Article
- Rheumatoid arthritis and risk of lung diseases in East Asians and Europeans: Evidence from a Mendelian randomization study.SAGE open medicine · 2026Article
- Trends in cardiovascular mortality related to rheumatoid arthritis among U.S. adults, 1999-2023.Frontiers in cardiovascular medicine · 2026Article
- Arthritis and increased risk of cardiovascular disease: is there an interaction with other chronic diseases? A nationwide cohort study.BMC cardiovascular disorders · 2025Article
- Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis.Journal of clinical medicine · 2025Review
- Healthcare Interventions in the Management of Rheumatic Diseases: A Narrative Analysis of Effectiveness and Emerging Strategies.Healthcare (Basel, Switzerland) · 2025Review
- Development and validation of a prognostic nomogram for predicting mortality risk in adult rheumatoid arthritis: an analysis of NHANES 1999-2018 data.Frontiers in immunology · 2025Article
- Connexin-43 Protein Expression Pattern Analysis in Myocardial Infarction Tissues.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo highlight advancements in managing traditional and rheumatoid arthritis (RA) specific risk factors and the impact of RA treatments on cardiovascular outcomes. RECENT
findingsAdvancements in rheumatoid arthritis management have paralleled declining trends in cardiovascular disease risks. Biomarkers like CRP, Lipoprotein(a), Apolipoprotein B 100, and imaging tools such as coronary artery calcium scoring enhance cardiovascular risk stratification, particularly in intermediate-risk RA patients. While effective RA treatments, have demonstrated substantial cardiovascular benefits, subclass differences were noted in high-risk patients. Increased risk of cardiovascular disease is driven by chronic inflammation, altered lipid metabolism, and traditional risk factors. Effective RA treatment significantly lowers cardiovascular events. Standard treatment of hypertension, diabetes and hypercholesterolemia are effective and lowers RA disease activity and inflammatory markers. While RA is considered a risk enhancing state in calculating CV risk scores, currently there exists no RA disease -specific blood pressure, blood sugar or lipid targets.
Indexed as
Identifiers
39831939What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.